Resveratrol-derived inhibitors of the E3 ubiquitin ligase PELI1 inhibit the metastasis of triple-negative breast cancer.

Eur J Med Chem

Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, No. 44 West Wenhua Road, Jinan, Shandong, 250012, China; State Key Laboratory of Microbial Technology, Shandong University, Qingdao, Shandong, 266237, China; NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Shandong University, Jinan, Shandong, 250012, China. Electronic address:

Published: February 2024

Triple-negative breast cancer (TNBC), as the most challenging subtype of breast cancer, exerts highly invasive ability and metastatic nature to the lymph nodes, which is correlated with poor survival rates among patients. Pellino-1 (PELI1) is an E3 ubiquitin ligase involved in tumor invasion and metastasis, and has the potential to be developed as a novel therapeutic target for TNBC. In this study, we identified a potent inhibitor of PELI1, namely compound 3d, on the basis of natural stilbene framework through medicinal chemistry approaches. This novel PELI1 inhibitor 3d showed potent binding affinity to PELI1 (K 8.2 μM) in fluorescence quenching assay, and markedly interrupted the interaction of PELI1 and SNAIL/SLUG confirmed by co-immunoprecipitation. Moreover, 3d exhibited potent antitumor activity in inhibiting tumor cell migration in scratch wound healing assay without affecting cell proliferation in vitro, and down-regulated the downstream EMT-effectors of PELI1 as assessed by western blotting. In the experimental lung metastasis model, 3d showed anti-TNBC metastasis efficacy without observable toxicity in vivo.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2023.116060DOI Listing

Publication Analysis

Top Keywords

breast cancer
12
ubiquitin ligase
8
triple-negative breast
8
peli1
7
resveratrol-derived inhibitors
4
inhibitors ubiquitin
4
ligase peli1
4
peli1 inhibit
4
metastasis
4
inhibit metastasis
4

Similar Publications

Tumor heterogeneity remains a formidable obstacle in targeted cancer therapy, often leading to suboptimal treatment outcomes. This study presents an innovative approach that harnesses controlled inflammation to guide neutrophil-mediated drug delivery, effectively overcoming the limitations imposed by tumor heterogeneity. By inducing localized inflammation within tumors using lipopolysaccharide, it significantly amplify the recruitment of drug-laden neutrophils to tumor sites, irrespective of specific tumor markers.

View Article and Find Full Text PDF

Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how changes in the Ki67 biomarker before and after neoadjuvant chemotherapy (NACT) affect survival in patients with triple-negative breast cancer (TNBC).
  • Among 1,777 TNBC patients analyzed, most showed a decrease in tumor size and Ki67 levels after NACT, though many had no change or experienced treatment discontinuation.
  • Patients with unchanged Ki67 had significantly worse overall and disease-specific survival compared to those with decreased Ki67, emphasizing the need for personalized treatment strategies based on ongoing monitoring of this biomarker.
View Article and Find Full Text PDF

Elevated MRPS23 expression facilitates aggressive phenotypes in breast cancer cells.

Cell Mol Biol (Noisy-le-grand)

January 2025

Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.

Mitochondrial ribosomal protein S23 (MRPS23), encoded by a nuclear gene, is a well-known driver of proliferation in cancer. It participates in mitochondrial protein translation, and its expression association has been explored in many types of cancer. However, MRPS23 expression associations are rarely reported in breast cancer (BC).

View Article and Find Full Text PDF

In this study, the effects of histone deacetylase inhibitor CI-994 and nanotechnological drug liposomal cisplatin LipoPlatin on Luminal A breast cancer and triple-negative breast cancer were explored using agents alone and in combination. MCF-7 and MDA-MB-231 cell lines were used. Cell viability, and cell index values obtained from xCELLigence System, MI, BrdU LI and AI were evaluated in experiments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!